Acronym:
BR.31
ACTRN/NCT /ethics:
ACTRN12615000323527NCT02273375
Scientific title:
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Summary of trial and patient characteristics
| Cancer Type | Lung & mesothelioma | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase III | Tumour Stream | Lung -Non Small Cell |
| Age Range | 18 years and older | Cancer Stage | All stages |
| Sex | Both | Anticipated Start Date | 2014-10-09 |
| Molecular Target | Anticipated End Date | 2025-01-01 | |
| Cancer Type | Lung & mesothelioma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Lung -Non Small Cell |
| Cancer Stage | All stages |
| Anticipated Start Date | 2014-10-09 |
| Anticipated End Date | 2025-01-01 |
Trial Summary
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Lay Summary
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Sponsor / Cooperative group
Canadian Cancer Trials Group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Professor Chris Karapetis | Recruiting |
| Royal Adelaide Hospital | Anne Milton | anne.milton@sa.gov.au | 08 7074 2342 | Brown | Recruiting |